Get the Stockscreener App
366.25
0.01%
0.04
After Hours:
366.25
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $366.25, with a volume of 2.09M.
It is up +0.01% in the last 24 hours and down -0.80% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$366.21
Open:
$369.38
24h Volume:
2.09M
Relative Volume:
0.76
Market Cap:
$197.43B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
25.73
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-2.84%
1M Performance:
-0.80%
6M Performance:
+34.12%
1Y Performance:
+16.75%
1-Day Range:
$364.72
$370.89
1-Week Range:
$364.72
$380.14
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
366.25 | 197.41B | 36.74B | 7.71B | 8.10B | 14.23 |
|
LLY
Lilly Eli Co
|
989.12 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.19 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
221.45 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.01 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.87 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen And Sanofi End Repatha IP Fight Heard By Justices - Law360
Here’s Why Amgen’s Free Cash Flow Could Nearly Double in 2026 - TIKR.com
Is Amgen Inc. (AMGN) a Good Buy at the Moment? - Bitget
Is Trending Stock Amgen Inc. (AMGN) a Buy Now? - Yahoo Finance Singapore
Biotechnology Market Is Booming So Rapidly | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report - Benzinga
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report - Benzinga
Hilltop Holdings Inc. Boosts Stock Position in Amgen Inc. $AMGN - MarketBeat
Elevation Point Wealth Partners LLC Buys 5,370 Shares of Amgen Inc. $AMGN - MarketBeat
Bank of Nova Scotia Purchases 60,794 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Decreased by Ameriprise Financial Inc. - MarketBeat
Amgen Inc. Stock Holds Defensive Ground Near 366 USD as Biotech Giant Targets 12% Annual Gain - AD HOC NEWS
Amgen TrumpRx Discounts Put Drug Pricing And Growth Story In Focus - simplywall.st
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies - Insider Monkey
Amgen’s TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN) - Yahoo Finance
Chevy Chase Trust Holdings LLC Sells 9,383 Shares of Amgen Inc. $AMGN - MarketBeat
California Public Employees Retirement System Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Boosts Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock (ISIN: US0311621009) Demonstrates Defensive Strength Amid Market Volatility - AD HOC NEWS
Aristotle Capital Management LLC Sells 153,136 Shares of Amgen Inc. $AMGN - MarketBeat
How Investors May Respond To Amgen (AMGN) Dividend, Obesity Drug Focus, And Cardiovascular Trial Updates - simplywall.st
Amgen (AMGN) and GSK (GSK) Expand Reach with TrumpRx Partnership - GuruFocus
Amgen and GSK said to be adding products on TrumpRx - Seeking Alpha
Amgen Inc. Stock (ISIN: US0311621009) Gains Defensive Appeal Amid Leadership Shift and Biotech Resil - AD HOC NEWS
M&T Bank Corp Trims Position in Amgen Inc. $AMGN - MarketBeat
Capital Wealth Planning Reduces Amgen Stake - National Today
Harvest Fund Management Co. Ltd Sells 4,234 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock Dips Amid TrumpRx Partnership News as Valuation Stands Firm - AD HOC NEWS
Comerica Bank Has $46.70 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Capital Wealth Planning LLC Sells 472,530 Shares of Amgen Inc. $AMGN - MarketBeat
GSK and Amgen to add medicines to TrumpRx, Fox Business reports - Reuters
Two major drug companies are the latest to join TrumpRx - Fox Business
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar - Law360
Amgen obtains EPA ENERGY STAR 2025 certification - WJournalpr
Amgen Inc. Stock (ISIN: US0311621009) Hits Defensive Strength Amid Biotech Shifts - AD HOC NEWS
Starbucks, Amgen, CVS and Other Stocks Help This Income Fund Shine - Barron's
Amgen vs Sanofi – A chronology of the patent battle over Repatha and Praluent - JUVE Patent
Amgen Inc. $AMGN Shares Sold by Martingale Asset Management L P - MarketBeat
Invesco Ltd. Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Mackenzie Financial Corp - MarketBeat
Amgen Inc. $AMGN Shares Bought by American Investment Services Inc. - MarketBeat
Advisory Research Inc. Makes New Investment in Amgen Inc. $AMGN - MarketBeat
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen and Sanofi end epic battle over Praluent and Repatha - JUVE Patent
Is It Time To Reassess Amgen (AMGN) After Its Strong 1 Year Share Price Run? - simplywall.st
Amgen: MariTide And Osteoporosis Sales Fuel The Rally (NASDAQ:AMGN) - Seeking Alpha
SevenBridge Financial Group LLC Decreases Position in Amgen Inc. $AMGN - MarketBeat
Franklin Resources Inc. Lowers Position in Amgen Inc. $AMGN - MarketBeat
Inceptionr LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference - MarketBeat
Kepler Cheuvreux Suisse SA Makes New $5 Million Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):